Crosstalking with dendritic cells: a path to engineer advanced T Cell immunotherapy

被引:1
|
作者
Schafer, Sogand [1 ,2 ]
Chen, Kaige [3 ]
Ma, Leyuan [3 ,4 ,5 ,6 ,7 ]
机构
[1] Childrens Hosp Philadelphia, Childrens Hosp Philadelphia Res Inst, Ctr Craniofacial Innovat, Philadelphia, PA USA
[2] Childrens Hosp Philadelphia, Dept Surg, Div Plast & Reconstruct Surg, Philadelphia, PA USA
[3] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[4] Univ Penn, Ctr Cellular Immunotherapies, Perelman Sch Med, Philadelphia, PA 19104 USA
[5] Univ Penn, Inst Immunol, Perelman Sch Med, Philadelphia, PA 19104 USA
[6] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA
[7] Childrens Hosp Philadelphia, Raymond G Perelman Ctr Cellular & Mol Therapeut, Philadelphia, PA 19104 USA
来源
FRONTIERS IN SYSTEMS BIOLOGY | 2024年 / 4卷
关键词
dendritic cell; cellular crosstalk; immunological synapse; nanoparticles; biomaterials; ANTIGEN-PRESENTING CELLS; RECEPTOR AFFINITY; CANCER; DIFFERENTIATION; MECHANISMS; VACCINE; AUTOIMMUNITY; LYMPHOCYTES; HOMEOSTASIS; ACTIVATION;
D O I
10.3389/fsysb.2024.1372995
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Crosstalk between dendritic cells and T cells plays a crucial role in modulating immune responses in natural and pathological conditions. DC-T cell crosstalk is achieved through contact-dependent (i.e., immunological synapse) and contact-independent mechanisms (i.e., cytokines). Activated DCs upregulate co-stimulatory signals and secrete proinflammatory cytokines to orchestrate T cell activation and differentiation. Conversely, activated T helper cells "license" DCs towards maturation, while regulatory T cells (Tregs) silence DCs to elicit tolerogenic immunity. Strategies to efficiently modulate the DC-T cell crosstalk can be harnessed to promote immune activation for cancer immunotherapy or immune tolerance for the treatment of autoimmune diseases. Here, we review the natural crosstalk mechanisms between DC and T cells. We highlight bioengineering approaches to modulate DC-T cell crosstalk, including conventional vaccines, synthetic vaccines, and DC-mimics, and key seminal studies leveraging these approaches to steer immune response for the treatment of cancer and autoimmune diseases.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Targeting T cell metabolism for immunotherapy
    Gao, Jie
    Liu, Yanbo
    Wei, Jian
    Jiang, Linlan
    Mao, Jianwen
    Chang, Chih-Hao
    Wu, Duojiao
    JOURNAL OF LEUKOCYTE BIOLOGY, 2021, 110 (06) : 1081 - 1090
  • [42] Dendritic cell-based immunotherapy
    Osada, Takuya
    Clay, Timothy M.
    Woo, Christopher Y.
    Morse, Michael A.
    Lyerly, H. Kim
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2006, 25 (5-6) : 377 - 413
  • [43] Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy
    Qian, Chen
    Yang, Li-Jun
    Cui, Hong
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [44] Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Takashi Morisaki
    Kotaro Matsumoto
    Hideya Onishi
    Hideo Kuroki
    Eishi Baba
    Akira Tasaki
    Makoto Kubo
    Mitsunari Nakamura
    Syoichi Inaba
    Koji Yamaguchi
    Masao Tanaka
    Mitsuo Katano
    Human Cell, 2003, 16 (4) : 175 - 182
  • [45] Dendritic cells control T cell tonic signaling required for responsiveness to foreign antigen
    Hochweller, Kristin
    Wabnitz, Guido H.
    Samstag, Yvonne
    Suffner, Janine
    Haemmerling, Guenter J.
    Garbi, Natalio
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (13) : 5931 - 5936
  • [46] Potential use of γδ T cell-based vaccines in cancer immunotherapy
    Khan, Mohd Wajid A.
    Eberl, Matthias
    Moser, Bernhard
    FRONTIERS IN IMMUNOLOGY, 2014, 5 : 1 - 5
  • [47] Review Dendritic cells as shepherds of T cell immunity in cancer
    Pittet, Mikael J.
    Di Pilato, Mauro
    Garris, Christopher
    Mempel, Thorsten R.
    IMMUNITY, 2023, 56 (10) : 2218 - 2230
  • [48] Nanoscale artificial antigen presenting cells for T cell immunotherapy
    Perica, Karlo
    Medero, Andres De Leon
    Durai, Malarvizhi
    Chiu, Yen Ling
    Bieler, Joan Glick
    Sibener, Leah
    Niemoeller, Michaela
    Assenmacher, Mario
    Richter, Anne
    Edidin, Michael
    Oelke, Mathias
    Schneck, Jonathan
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2014, 10 (01) : 119 - 129
  • [49] Aminobisphosphonate-pretreated dendritic cells trigger successful Vγ9Vδ2 T cell amplification for immunotherapy in advanced cancer patients
    Cabillic, Florian
    Toutirais, Olivier
    Lavoue, Vincent
    de La Pintiere, Cecile Thomas
    Daniel, Pascale
    Rioux-Leclerc, Nathalie
    Turlin, Bruno
    Monkkonen, Hannu
    Monkkonen, Jukka
    Boudjema, Karim
    Catros, Veronique
    Bouet-Toussaint, Francoise
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (11) : 1611 - 1619
  • [50] IMMUNOTHERAPY USING ALLOGENEIC SQUAMOUS CELL TUMOR-DENDRITIC CELL FUSION HYBRIDS
    Lee, Walter T.
    Tan, Chunrui
    Koski, Gary
    Shu, Suyu
    Cohen, Peter
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2010, 32 (09): : 1209 - 1216